Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY23 results · Oct–Dec 2022
Torrent Pharmaceuticals reported revenue from operations of ₹2,491.00 crore (up 18.2% from Q3 FY22) and net profit of ₹283.00 crore (up 13.7% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,491.00 | 2,108.00 | +18.2% | 2,291.00 | +8.7% |
| Other income | (10.00) | 48.00 | Turned loss | 16.00 | Turned loss |
| Total income | 2,481.00 | 2,156.00 | +15.1% | 2,307.00 | +7.5% |
| Profit before tax | 419.00 | 357.00 | +17.4% | 463.00 | −9.5% |
| Net profit for the period | 283.00 | 249.00 | +13.7% | 312.00 | −9.3% |
| EPS, basic (₹) | 8.36 | 14.75 | not comparable | 9.22 | −9.3% |
| Net margin (%) | 11.4 | 11.8 | 13.6 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,857.00 | 1,588.00 | +16.9% | 1,928.00 | −3.7% |
| Other income | 15.00 | 37.00 | −59.5% | 11.00 | +36.4% |
| Total income | 1,872.00 | 1,625.00 | +15.2% | 1,939.00 | −3.5% |
| Profit before tax | 353.00 | 255.00 | +38.4% | 413.00 | −14.5% |
| Net profit for the period | 229.00 | 170.00 | +34.7% | 272.00 | −15.8% |
| EPS, basic (₹) | 6.78 | 10.06 | not comparable | 8.02 | −15.5% |
| Net margin (%) | 12.3 | 10.7 | 14.1 |
Consolidated
- Filed with BSE
- 27 Jan 2023, 11:36 IST
- Board meeting
- 25 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2023, 11:36 IST
- Board meeting
- 25 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Audited
- Source
- XBRL filing on BSE